You just read:

Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial

News provided by

Cempra Pharmaceuticals

May 07, 2011, 05:30 ET